Farkas Klaudia, Rutka Mariann, Ferenci Tamás, Nagy Ferenc, Bálint Anita, Bor Renáta, . . . Molnár Tamás. (2017). Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center.
Chicago Style (17th ed.) CitationFarkas Klaudia, et al. Infliximab Biosimilar CT-P13 Therapy Is Effective and Safe in Maintaining Remission in Crohn’s Disease and Ulcerative Colitis – Experiences from a Single Center. 2017.
MLA idézésFarkas Klaudia, et al. Infliximab Biosimilar CT-P13 Therapy Is Effective and Safe in Maintaining Remission in Crohn’s Disease and Ulcerative Colitis – Experiences from a Single Center. 2017.
Figyelem: ezek az hivatkozások nem 100%-ban pontosak..